IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Disc Medicine, Inc. due to allegations of materially misleading business information issued to the investing public [1] Group 1: Legal Action and Investor Rights - Shareholders who purchased Disc Medicine securities may be entitled to compensation through a contingency fee arrangement, with a class action being prepared to recover investor losses [2] - Investors are encouraged to join the prospective class action by contacting Rosen Law Firm for more information [2] Group 2: Regulatory Issues - On February 13, 2026, the FDA issued a Complete Response Letter to Disc Medicine regarding its bitopertin program, stating that the new drug application could not be approved due to uncertainties requiring additional evidence [3] - Following the FDA's announcement, Disc Medicine's stock price experienced a significant decline of 22% on the same day [3] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting their experience and recognition in the field [4] - The firm has achieved notable settlements for investors, including over $438 million in 2019, and has been consistently ranked among the top firms for securities class action settlements [4]